Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 3Fallopian Tube Neoplasms 2Neoplasms 1Glioblastoma 1Endometrial Adenocarcinoma 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Taxes 5Paclitaxel 5Carboplatin 4Cisplatin 3Immunoglobulin G 2Doxorubicin 2Disulfides 2Bevacizumab 2trastuzumab biosimilar HLX02 1trametinib 1temsirolimus 1pegfilgrastim 1nintedanib 1linrodostat 1ixabepilone 1cediranib 1brivanib 1Trastuzumab 1Sunitinib 1Sirolimus 1Radiotherapy, Intensity-Modulated 1Radiotherapy 1Radiation 1Platinum 1PF-05280014 1Ontruzant 1Ogivri 1Nivolumab 1Metformin 1Medroxyprogesterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Adenocarcinoma × MK 2206 × Gynecologic × Clear all
NCT01307631 2022-02-11

Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Completed
37 enrolled 9 charts
Gynecologic

Endometrial Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡